馬泰勒蟲免疫熒光玻片
| 型 號(hào)： | |
| 報(bào) 價(jià)： |  |
馬泰勒蟲免疫熒光玻片 立克次體 巴爾通體 需要了解更多產(chǎn)品可以咨詢我們，本產(chǎn)品由廣州健侖生物科技有限公司提供
- 產(chǎn)品描述
馬泰勒蟲免疫熒光玻片
theileria equi IFA Substrate slide
廣州健侖生物科技有限公司
主要用途：用于檢測(cè)馬血清中的馬泰勒蟲IgG/IgM抗體
產(chǎn)品規(guī)格：12 孔/張,10 張/盒
主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。
馬泰勒蟲免疫熒光玻片
我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢2042552662
| JL-FL54 | 牛雙芽巴貝西蟲免疫熒光玻片 | babesia bigemina IFA Substrate slide |
| JL-FL55 | 牛雙芽巴貝西蟲免疫熒光試劑盒 | babesia bigemina IFA Kit |
| JL-FL56 | 牛巴貝西蟲免疫熒光玻片 | babesia bovis IFA Substrate slide |
| JL-FL57 | 牛巴貝西蟲免疫熒光試劑盒 | babesia bovis IFA Kit |
| JL-FL58 | 駑巴貝西蟲免疫熒光玻片 | babesia caballi IFA Substrate slide |
| JL-FL59 | 駑巴貝西蟲免疫熒光試劑盒 | babesia caballi IFA Kit |
| JL-FL60 | theileria equi IFA Substrate slide | |
| JL-FL61 | 馬泰勒蟲免疫熒光試劑盒 | theileria equi IFA Kit |
| JL-FL62 | 利什曼蟲IgG免疫熒光試劑盒 | Leishmania IgG IFA Kit |
| JL-FL63 | 新孢子蟲IgG免疫熒光試劑盒（檢測(cè)狗） | Neospora caninum IgG IFA Kit |
| JL-FL64 | 新孢子蟲IgG免疫熒光試劑盒（檢測(cè)馬） | Neospora caninum IgG IFA Kit |
| JL-FL65 | 貓杯狀病毒IgG免疫熒光玻片 | Feline Calicivirus IgG IFA Substrate slide |
| JL-FL66 | 貓冠狀病毒IgG免疫熒光玻片 | Feline Coronavirus IgG IFA Substrate slide |
| JL-FL67 | 貓皰疹病毒IgG免疫熒光玻片 | Feline Herpesvirus IgG IFA Substrate slide |
| JL-FL68 | 犬瘟病毒IgG免疫熒光玻片 | Canine Distemper IgG IFA Substrate slide |
| JL-FL69 | 犬細(xì)小病毒IgG免疫熒光玻片 | Canine Parvovirus IgG IFA Substrate slide |
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】
但是，Raz及其同事們發(fā)現(xiàn)，TPRV1也在腸道上皮細(xì)胞表達(dá)，在那里它被表皮生長(zhǎng)因子受體(EGFR)激活。EGFR是腸道中細(xì)胞增殖的一個(gè)重要驅(qū)動(dòng)力，大約每四到六天，腸道上皮層就被替換。
本文*作者Petrus de Jong博士稱：“保持腸道內(nèi)正常細(xì)胞更新，需要一個(gè)基本水平的EGFR活性。然而，如果EGFR信號(hào)是無限制的，散發(fā)性腫瘤的發(fā)展風(fēng)險(xiǎn)就會(huì)增加。”
科學(xué)家們發(fā)現(xiàn)，一旦TRPV1被EGFR激活，可引發(fā)一種對(duì)EGFR的直接負(fù)反饋，從而抑制后者降低不必要的生長(zhǎng)和腸道腫瘤發(fā)展風(fēng)險(xiǎn)。他們發(fā)現(xiàn)，缺乏TRPV1的轉(zhuǎn)基因小鼠，腸道腫瘤的生長(zhǎng)率高于正常。
de Jong稱：“這些結(jié)果表明，上皮TRPV1通常作為腸道內(nèi)的一個(gè)腫瘤抑制基因。”此外，zui近對(duì)人結(jié)腸直腸癌樣本的分子研究，發(fā)現(xiàn)了TRPV1基因中的多個(gè)突變，然而Raz指出，目前還沒有直接的證據(jù)表明，TRPV1缺陷是人類結(jié)直腸癌的危險(xiǎn)因素。他說：“在今后的臨床研究中，應(yīng)該解決TRPV1功能和人結(jié)直腸癌之間的直接關(guān)聯(lián)。”
但是，如果這是事實(shí)的話，當(dāng)前的研究指出，一種潛在的治療方法可能是辣椒素，它作為哺乳動(dòng)物的一種刺激物，與組織接觸產(chǎn)生一種灼熱感。辣椒素已被廣泛用作外用藥膏的鎮(zhèn)痛藥，其性質(zhì)是作為一種壓倒神經(jīng)的刺激物，使神經(jīng)不能長(zhǎng)時(shí)間的疼痛。它也是胡椒噴霧劑的活性成分。
研究人員給遺傳上更傾向于患多種胃腸道腫瘤的小鼠喂食辣椒素。這種治療方法導(dǎo)致腫瘤負(fù)擔(dān)減少，使小鼠的壽命延長(zhǎng)了超過30%。當(dāng)聯(lián)合塞來昔布(celecoxib，一種COX-2非甾體類抗炎藥物，已被批準(zhǔn)用于治療一些形式的關(guān)節(jié)炎和疼痛)使用時(shí)，治療更加有效。
在一個(gè)共同合作中，研究人員在紐約州立大學(xué)水牛城分校的莫成?帕特爾博士以及勞森健康研究院和加拿大西安大略大學(xué)的大衛(wèi)?希爾博士的帶領(lǐng)之下，評(píng)估粒線體中的綜合酵素--丙酮酸脫氫酶復(fù)合體在小鼠新生期間如何調(diào)控胰島的β細(xì)胞的發(fā)育和成熟。
However, Raz and colleagues found that TPRV1 is also expressed in intestinal epithelial cells, where it is activated by the epidermal growth factor receptor (EGFR). EGFR is an important driver of cell proliferation in the gut, and the gut epithelium is replaced every about four to six days.
"The maintenance of normal cell renewal in the intestine requires a basic level of EGFR activity, but if the EGFR signal is unrestricted, the risk of developing sporadic tumors is increased," said lead author Petrus de Jong.
Scientists have found that once TRPV1 is activated by EGFR, it can trigger a direct negative feedback on EGFR, thereby inhibiting the latter from reducing the risk of unnecessary growth and intestinal tumor development. They found that, in the absence of TRPV1 transgenic mice, the growth rate of intestinal tumors was higher than normal.
"These results show that epithelial TRPV1 is often used as a tumor suppressor in the gut." In addition, a recent molecular study of human colorectal cancer samples revealed multiple mutations in the TRPV1 gene, de Jong said. However, Raz noted that at present There is no direct evidence that TRPV1 deficiency is a risk factor for human colorectal cancer. He said: "In future clinical studies, a direct link between TRPV1 function and human colorectal cancer should be addressed."
However, if this is true, current research suggests that one potential treatment may be capsaicin, a stimulant of mammals that comes into contact with the tissue to create a burning sensation. Capsaicin has been widely used as an analgesic for topical ointments, which act as an overwhelming stimulant that prevents the nerves from prolonged pain. It is also the active ingredient of pepper spray.
Researchers fed caprine to mice genetically more prone to multiple gastrointestinal tumors. This treatment led to reduced tumor burden, extending the lifespan of mice by more than 30%. The treatment is more effective when used in combination with celecoxib (a COX-2 NSAID that has been approved for the treatment of some forms of arthritis and pain).
In a joint effort, researchers under the leadership of Dr. Mo Cheng Pa, of the State University of New York at Buffalo, and Dr. David Hill of the Lawson Health Institute and the University of Western Ontario in Canada, In the synthesis of enzymes - pyruvate dehydrogenase complex in mouse neonatal period how the regulation of islet β cell development and maturation.
